CM
NKTR icon

CM Management’s Nektar Therapeutics NKTR Stock Holding History

CM Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45,000
Closed -$1.16M – 75
2025
Q2 		$1.16M Sell
45,000
-8,333
-16% -$93.6K 1.06% 33
2025
Q1 		$544K Buy
53,333
+3,333
+7% +$43.5K 0.55% 44
2024
Q4 		$698K Hold
50,000
– – 0.62% 45
2024
Q3 		$975K Hold
50,000
– – 0.78% 46
2024
Q2 		$930K Sell
50,000
-12,656
-20% -$267K 0.85% 42
2024
Q1 		$878K Hold
62,656
– – 0.74% 45
2023
Q4 		$531K Buy
62,656
+9,323
+17% +$70.6K 0.43% 54
2023
Q3 		$476K Buy
53,333
+3,333
+7% +$32.1K 0.51% 48
2023
Q2 		$431K Buy
50,000
+23,333
+87% +$249K 0.42% 55
2023
Q1 		$281K Buy
26,667
+18,334
+220% +$555K 0.33% 54
2022
Q4 		$283K Buy
8,333
+5,000
+150% +$242K 0.34% 60
2022
Q3 		$160K Sell
3,333
-5,000
-60% -$297K 0.18% 71
2022
Q2 		$475K Buy
8,333
+3,333
+67% +$210K 0.51% 57
2022
Q1 		$404K Buy
5,000
+3,333
+200% +$493K 0.34% 69
2021
Q4 		$338K Sell
1,667
-1,666
-50% -$361K 0.26% 79
2021
Q3 		$898K Hold
3,333
– – 0.67% 56
2021
Q2 		$858K Hold
3,333
– – 0.62% 58
2021
Q1 		$1M Buy
3,333
+1,000
+43% +$311K 0.74% 57
2020
Q4 		$595K Buy
+2,333
New +$603K 0.55% 56

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CM Management's NKTR Position: Q3 2025 in Review

CM Management sold out of Nektar Therapeutics (NKTR) in Q3 2025, closing a stake of 45,000 shares — an estimated $1.16M sold.

CM Management first reported a position in NKTR in Q4 2020 and held it in 19 quarters. The position peaked at $1.16M in Q2 2025. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • CM Management reported no remaining Nektar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CM Management sold 45,000 Nektar Therapeutics shares in Q3 2025, an estimated $1.16M.
  • CM Management first reported a position in Nektar Therapeutics in Q4 2020 and held it in 19 quarters.
  • CM Management's Nektar Therapeutics position peaked at $1.16M in Q2 2025.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on CM Management's 13F filing for Q3 2025, filed 13 Nov 2025.